Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for…
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 ---- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, due upon FDA acceptance of KPI-012 IND…